<DOC>
	<DOC>NCT01750580</DOC>
	<brief_summary>To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.</brief_summary>
	<brief_title>Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Histologic confirmation of one of the following solid tumors that is advanced (unresectable or metastatic) for dose escalation or cohort expansion:NonSmall Cell Lung Cancer (NSCLC), Castrate Resistant Prostate Cancer (CRPC), Melanoma (MEL) At least one measurable lesion at baseline by Computed tomography (CT) or Magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria Biopsies: Subjects in the melanoma cohort must have at least 1 tumor site that can be biopsied at acceptable clinical risk Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 Estimated life expectancy of ≥ 12 weeks White blood cell (WBC) ≥2000/μL, Neutrophils ≥1500/μL, Platelets ≥ 100x1000/μL, Hemoglobin ≥ 8.5 g/dL, creatinine ≤ 1.5 X upper limit of normal (ULN) mL/min, Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 3x ULN Normal thyroid function or be on stable hormone supplementation Participation in any prior clinical study with BMS936558 or ipilimumab that has overall survival listed as a primary/coprimary endpoint Subjects with known or suspected brain metastasis Subjects with active autoimmune disease, uncontrolled or significant cardiovascular disease Prior therapy with anti Cytotoxic TLymphocyte Antigen 4 (CTLA4) antibody or anti Killer cell immunoglobulinlike receptor (KIR) antibody Grade 2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>